Boston Scientific Spinal Cord Stimulator Lawsuit
Updated November 2, 2026. Boston Scientific was the first spinal cord stimulator manufacturer with a federal MDL; Abbott and Nevro now have separate MDLs (MDL-3194 and MDL-3195). MDL-3181 was created on June 5, 2026 before Judge Josephine L. Staton in the Central District of California, with 62 actions pending as of November 2026. The initial scheduling conference was held August 5, 2026, and plaintiffs' leadership was appointed August 13. Every complaint alleges that sales representatives practiced medicine without a license. There is no verdict and no settlement in the tort.
Key Takeaways
- MDL-3181 against Boston Scientific, before Judge Staton (C.D. Cal.), created June 5, 2026, was the first spinal cord stimulator MDL; Abbott (MDL-3194) and Nevro (MDL-3195) now have separate MDLs before other judges
- 62 cases pending as of November 2026, a very small docket by MDL standards
- Named complaints reference the WaveWriter and WaveWriter Alpha; the JPML order named no specific models
- Every complaint pleads the unlicensed-practice-of-medicine theory against sales representatives; no court has endorsed it on the merits
- The FDA classified Boston Scientific's 2026 removal of unused Infinion CX leads as a Class I recall; implanted leads are not affected. There is no verdict or settlement
The first SCS MDL
MDL-3181 was the first federal spinal cord stimulator MDL. The JPML created it on June 5, 2026 and assigned it to Judge Josephine L. Staton in the Central District of California. The order identified two shared factual questions running through the Boston Scientific cases: whether the premarket approval was built in part on other manufacturers' clinical literature, and whether the company used the premarket-approval supplement process to introduce significantly modified devices without fresh clinical evaluation. The docket was originally captioned to include Abbott and was renamed to Boston Scientific only when the Panel declined to centralize the Abbott cases on procedural grounds. On October 2, 2026, after its September 24 hearing session, the Panel created separate MDLs for Abbott (MDL-3194, Northern District of Illinois, Judge Lindsay C. Jenkins) and Nevro (MDL-3195, Northern District of California, Judge Haywood S. Gilliam, Jr.), and declined to send either to Judge Staton.
The initial scheduling conference was held on August 5, 2026. On August 13, Pretrial Order No. 2 appointed plaintiffs' leadership: co-lead counsel Behram Parekh (Wisner Baum), Adam Evans (Carlson Law Firm) and Carasusana Wall (Bullock Legal Group), liaison counsel Ashleigh Raso, and executive, steering and leadership-development committees.
Since then the court has split the MDL into two tracks. Under Pretrial Order No. 5 (September 23, 2026) and Pretrial Order No. 6 (October 20, 2026), the product-liability claims against Boston Scientific proceed on a Personal Injury Track, and plaintiffs' Administrative Procedure Act claims against the FDA proceed on a separate APA Track. Motions to dismiss are due November 20, 2026; on the APA Track, the FDA and Boston Scientific motions will be heard no earlier than February 5, 2027, according to Pretrial Order No. 5. Pretrial Order No. 6 also lets the defendants pursue statute-of-limitations motions to dismiss in cases that name Boston Scientific alongside Abbott or Nevro. Judge Staton has not yet issued a substantive ruling.
Devices
Named complaints reference the WaveWriter and WaveWriter Alpha. The broader Boston Scientific line is reported to include Precision Montage and Spectra WaveWriter. The transfer order does not name specific models, so we treat model-level identification within the pleadings as unconfirmed. The specific device you had is recorded in your implant and device records.
On recalls: in 2026 the FDA classified Boston Scientific's removal of unused Infinion CX leads as a Class I recall, its most serious category. Boston Scientific notified customers on June 17, 2026, citing lead-body stress at the anchor site that may cause high impedance readings or lead fractures. According to the FDA, the action covers unused leads only and does not affect leads already implanted, and Boston Scientific had reported 1,081 serious injuries and no deaths associated with the issue as of May 27, 2026. Boston Scientific also had a Class II recall of WaveWriter Alpha generator kits in 2024.
The sales-representative theory
The distinctive allegation in MDL-3181, pleaded in every complaint, is that Boston Scientific sales representatives practiced medicine without a license: entering surgical suites, advising surgeons on intraoperative lead positioning, programming devices, and adjusting stimulation parameters. No court has endorsed the unlicensed-practice-of-medicine theory on the merits, and in one case against a different manufacturer it was dismissed for lack of a private right of action. A narrower theory, that the manufacturer failed to train its representatives, was allowed to proceed as ordinary negligence in DiToto v. Nevro. Whether Judge Staton accepts any version of this theory is one of the open questions in the MDL.
Filing deadline and status
There is no verdict and no settlement in spinal cord stimulator litigation against any manufacturer. On timing, a July 14, 2026 order by Judge Schiltz in Minnesota applied one-year state limitations periods and started the clock when a patient was advised to turn the device off or developed dramatic new symptoms, rather than at explant. That analysis will not apply in every state, but it makes the filing timeline more urgent than the two-to-four-year windows advertised on many firm pages.
Frequently Asked Questions
Is there a Boston Scientific spinal cord stimulator MDL?
Which Boston Scientific devices are involved?
What is the sales representative allegation?
Have there been any Boston Scientific settlements or verdicts?
Sources & References
5 sources cited• JPML transfer order creating MDL-3181 (June 5, 2026)
• U.S. District Court, Central District of California: MDL-3181 docket, Judge Josephine L. Staton, including Pretrial Order No. 2 (August 13, 2026), Pretrial Order No. 5 (September 23, 2026) and Pretrial Order No. 6 (October 20, 2026)
• FDA recall notice, Boston Scientific Infinion CX leads (Class I; September 3, 2026), and FDA Medical Device Recall Database
• MDL-3181 complaints describing the WaveWriter devices and the sales-representative allegations
• Judicial Panel on Multidistrict Litigation: November 2026 MDL statistics
Attorney Advertising. The information on this page is provided for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by accessing or using this content.
Every case is unique, and results depend on the specific facts and circumstances involved. Past settlement amounts and case outcomes do not guarantee similar results in your case. If you believe you have a legal claim, you should consult with a licensed attorney in your jurisdiction who can evaluate your specific situation.